Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology
company developing induced pluripotent stem cell (iPSC)-derived
cell therapies in immuno-oncology and autoimmune and inflammatory
diseases, today announced that preclinical data from the Company’s
iPSC-derived cell therapy platform will be presented in six posters
at the upcoming 2024 American Association for Cancer Research
(AACR) Annual Meeting being held April 5-10, 2024, in San Diego,
CA. The upcoming abstracts highlight the Company’s end-to-end
capabilities in iPSC reprogramming and differentiation, gene
editing, protein engineering and computational biology.
Additionally, the Company will share new preclinical data on
additional Allo-Evasion™ edits that could further support Century’s
multi-dosing strategy.
Details of the poster presentations are as follows:
Abstract Number: 36Title: The Discovery of A Novel CD19xCD22
Dual-Targeting CAR For The Development Of An iPSC-Derived Cell
Therapy Poster Board Number: 4Session Title: Adoptive
Cell Therapies 2: CAR-T CellsSession Date: Sunday, April 7,
2024Session Time: 1:30 PM - 5:00 PM PT
Abstract Number: 1320Title: Engineered Expression Of HLA-E And
HLA-G Protects iPSC-Derived Cells from Killing By Primary NK Cells
Poster Board Number: 3Session Title: CAR-K, NK Engagers, and
NK ModulatorsSession Date: Monday, April 8, 2024 Session Time: 9:00
AM - 12:30 PM PT
Abstract Number: 3613Title: Screening iPSC Lines for Optimal
Characteristics of Differentiation into Immune Effector Cells for
Clinical Programs Poster Board Number: 19Session Title:
Adoptive Cellular Therapy 1Session Date: Monday, April 8, 2024
Session Time: 1:30 PM - 5:00 PM PT
Abstract Number: 1916Title: Discovery of a Novel Nectin4
iPSC-derived Cell Therapy for the Treatment of Solid Tumors Poster
Board Number: 27Session Title: Antibody Drug Conjugates
and Bispecific AntibodiesSession Date: Monday, April 8,
2024Session Time: 9:00 AM - 12:30 PM PT
Abstract Number: 4009Title: Discovery Of Inhibitory CAR Target
DSG1 For Damping NECTIN4 On-Target Off-Tumor Toxicity in
iPSC-Derived CAR-T Cell Therapy Poster Board Number: Section 2,
18Session Title: Adoptive Cell Therapies 3: CAR-T CellsSession
Date: Tuesday, April 9, 2024Session Time: 9:00 AM -12:30 PM PT
Abstract Number: 6802Title: CXCR4 Transgene Improves In
Vivo Migration and Efficacy of Engineered iPSC-Derived Natural
Killer Cells Poster Board Number: 7Session Title: Chemokines
and Cytokines in CancerSession Date: Wednesday, April 10, 2024
Session Time: 9:00 AM - 12:30 PM PT
Full abstracts are currently available through the AACR
conference website.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of
adult stem cells to develop curative cell therapy products for
cancer and autoimmune and inflammatory diseases that we believe
will allow us to overcome the limitations of first-generation cell
therapies. Our genetically engineered, iPSC-derived cell product
candidates are designed to specifically target hematologic and
solid tumor cancers, with a broadening application to autoimmune
and inflammatory diseases. We are leveraging our expertise in
cellular reprogramming, genetic engineering, and manufacturing to
develop therapies with the potential to overcome many of the
challenges inherent to cell therapy and provide a significant
advantage over existing cell therapy technologies. We believe our
commitment to developing off-the-shelf cell therapies will expand
patient access and provide an unparalleled opportunity to advance
the course of cancer and autoimmune and inflammatory disease care.
For more information on Century Therapeutics please visit
www.centurytx.com.
Century Therapeutics Forward-Looking
Statement
This press release contains forward-looking statements within
the meaning of, and made pursuant to the safe harbor provisions of,
The Private Securities Litigation Reform Act of 1995. All
statements contained in this press release, other than statements
of historical facts or statements that relate to present facts or
current conditions, including but not limited to, statements
regarding our clinical development plans and timelines, are
forward-looking statements. These statements involve known and
unknown risks, uncertainties and other important factors that may
cause our actual results, performance, or achievements to be
materially different from any future results, performance or
achievements expressed or implied by the forward-looking
statements. In some cases, you can identify forward-looking
statements by terms such as “may,” “might,” “will,” “should,”
“expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,”
“target,” “project,” “contemplate,” “believe,” “estimate,”
“predict,” “forecast,” “potential” or “continue” or the negative of
these terms or other similar expressions. The forward-looking
statements in this press release are only predictions. We have
based these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control, including, among others: our ability to
successfully advance our current and future product candidates
through development activities, preclinical studies, and clinical
trials; our dependence on the success of our lead product
candidate, CNTY-101; the ability of CNTY-101 to be administered as
part of a multi-dose strategy and to enable responses without
lymphodepletion; uncertainties inherent in the results of
preliminary data, pre-clinical studies and earlier-stage clinical
trials, which may not be predictive of final results or the results
of later-stage clinical trials; the timing of and our ability to
initiate and successfully enroll the Phase 1 SLE trial; our ability
to obtain FDA clearance of our future IND submissions and commence
and complete clinical trials on expected timelines, or at all; our
reliance on the maintenance of certain key collaborative
relationships for the manufacturing and development of our product
candidates; the timing, scope and likelihood of regulatory filings
and approvals, including final regulatory approval of our product
candidates; the impact of geopolitical issues, banking instability
and inflation on our business and operations, supply chain and
labor force; the performance of third parties in connection with
the development of our product candidates, including third parties
conducting our clinical trials as well as third-party suppliers and
manufacturers; our ability to successfully commercialize our
product candidates and develop sales and marketing capabilities, if
our product candidates are approved; our ability to recruit and
maintain key members of management and our ability to maintain and
successfully enforce adequate intellectual property protection.
These and other risks and uncertainties are described more fully in
the “Risk Factors” section of our most recent filings with the
Securities and Exchange Commission and available at www.sec.gov.
You should not rely on these forward-looking statements as
predictions of future events. The events and circumstances
reflected in our forward-looking statements may not be achieved or
occur, and actual results could differ materially from those
projected in the forward-looking statements. Moreover, we operate
in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
For More Information: Investors/Media: Julie
Seidel/Noor Pahlavi – century@argotpartners.com
Grafico Azioni Century Therapeutics (NASDAQ:IPSC)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Century Therapeutics (NASDAQ:IPSC)
Storico
Da Set 2023 a Set 2024